These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 21223692

  • 1. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L, Song LH, Ding SC, Zhang XJ, Qiang L, Han CY, Yuan XT, Xu DD.
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N.
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [Abstract] [Full Text] [Related]

  • 3. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, Inoue K, Uenishi T, Wakasa K, Suehiro S.
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
    Hang ZQ, Zheng MF, Huang JH.
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
    [Abstract] [Full Text] [Related]

  • 6. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi M.
    Cancer; 2006 Dec 15; 107(12):2842-9. PubMed ID: 17103443
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.
    Yi Y, Li B, Wang Z, Sun H, Gong H, Zhang Z.
    Biomarkers; 2009 Nov 15; 14(7):480-5. PubMed ID: 19863186
    [Abstract] [Full Text] [Related]

  • 11. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients].
    Duan X, Cui Y, Gong M, Tian F, Shi G, Wu B, Liu M, Guo J, Kong Y.
    Zhongguo Fei Ai Za Zhi; 2015 Jun 15; 18(6):358-64. PubMed ID: 26104892
    [Abstract] [Full Text] [Related]

  • 12. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer.
    Ando S, Kimura H, Iwai N, Yamamoto N, Iida T.
    Anticancer Res; 2003 Jun 15; 23(3C):2869-74. PubMed ID: 12926125
    [Abstract] [Full Text] [Related]

  • 13. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
    Song LH, Song XR, Liu MQ, Zhang XQ, Zheng L, Li XJ, Liu PX.
    Zhonghua Zhong Liu Za Zhi; 2004 Jun 15; 26(6):345-8. PubMed ID: 15312344
    [Abstract] [Full Text] [Related]

  • 14. Clinical value of serum cytokeratin 19 fragment and sialyl-Lewis x in non-small cell lung cancer.
    Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, Inoue K, Kameyama M, Suehiro S.
    Ann Thorac Surg; 2007 Jan 15; 83(1):216-21. PubMed ID: 17184666
    [Abstract] [Full Text] [Related]

  • 15. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
    Li R, Li R, Wang Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan 15; 21(1):26-9. PubMed ID: 11263296
    [Abstract] [Full Text] [Related]

  • 16. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F, Li WM, Wang DM, Gao SS, Bao Y, Chen WB, Liu D.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep 15; 39(5):832-5. PubMed ID: 19024326
    [Abstract] [Full Text] [Related]

  • 17. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
    Zhao T, Mao G, Chen M.
    Comput Math Methods Med; 2021 Sep 15; 2021():1951364. PubMed ID: 34603482
    [Abstract] [Full Text] [Related]

  • 18. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B, Huang AM, Zhong RB, Han BH.
    Chemotherapy; 2010 Sep 15; 56(6):417-23. PubMed ID: 21079400
    [Abstract] [Full Text] [Related]

  • 19. Relationship between N-linked oligosaccharide chains of human serum immunoglobulin G and serum tumor markers with non-small cell lung cancer progression.
    Kanoh Y, Ohara T, Mashiko T, Abe T, Masuda N, Akahoshi T.
    Anticancer Res; 2006 Sep 15; 26(6B):4293-7. PubMed ID: 17201147
    [Abstract] [Full Text] [Related]

  • 20. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG, Chen HL, Lu HY.
    BMC Cancer; 2015 May 10; 15():386. PubMed ID: 25956656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.